10598781 - GAU: 1626

Receipt date: 03/09/2007

Substitute for form 1449/PTO

1

. . . .

Sheet

PTO/SB/08A/B (09-06) Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE s are required to respond to a collection of information unless it contains a valid OMB control number

Attorney Docket Number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of

1

10/598.781-Conf. #1292 Application Number Filing Date September 11, 2006 Ania Fecher First Named Inventor Art Unit Net-Wet-Accioned Not Yet Assigned STOCKTON Examiner Name

A0345.0029

Complete if Known

U.S. PATENT DOCUMENTS Pages, Columns, Lines, Where Document Number Publication Date MM-DD-YYYY Name of Patentee or Examiner Cite Relevant Passages or Relevant Number-Kind Code² (If known) Applicant of Cited Document Initials* No Figures Appear

		FOREIG	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁹ -Kind Code ⁵ (il known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Whore Relevant Passages or Relevant Figures Appear	T°
	BA	-WO 95/07294	03-16-1995			

*EXAMINE: Initial Inference considered, whether or not clation is in conformance with MPEP USE. Juriar lines intrody-security (processed for considered, include copy of this form when ext communication to applicant. *Negliciar's unique clation designation number (optional). *See Kinds Codes of USPTO Patient Documents at www.uspng.gog/ or MPEP 901.04. *Enter Office that issued the document, by the wo-letter code (WIPO Sandard ST.3). *For USPTO Patient Documents at www.uspng.gog/ or with the second of the "https://www.morra.documents." Also and the "https://www.morra.documents." Also and uspng. of documents. Japanese patent documents, the indication of the year of the reign of the Emperor must preced the serial number serial patent documents, be indicated on the document under WIPO Standard ST.18 if possible. *Applicant is to place a check mark here if English language Translation is attached

		NON PATENT LITERATURE DOCUMENTS		1
Examiner Initials	Cite No.1			
	CA	Philip L. Gould., International Journal of Pharmaceutics, Vol. 33, pgs. 201-217 (1986)		1
	СВ	Warawa et al., J. Med. Chem., Vol. 44, pgs. 372-389 (2001)		
	CC	Gastpar et al., J. Med. Chem., Vol. 41, pgs. 4965-4972 (1998)		
	CD	Richard C. Larock et al., "Comprehensive Organic Transformations: A Guide to Functional Group Preparations", Wiley-VCH publishers, Second Edition (1999) Table of Conter	ts	on
	CE	Berge et al., Journal of Pharmaceutical Sciences, Vol. 66, pgs. 1-19 (1977)		
	CF	Sawyer et al., British Journal of Pharmacology, Vol. 137, pgs. 1163-1172 (2002)		
	CG	Sugimoto et al., The Journal of Pharmacology and Experimental Therapeutics, Vol. 305, No. 1, pgs. 347-352 (2003)		
	СН	Hans Bundgaard, "Design of Prodrugs", Elsevier, pgs. 7-9, 21-24 (1985)		
	CI	Moriya et al., Chem. Pharm. Bull., Vol. 28, No. 6, pgs. 1711-1721 (1980)		
	CJ	R.B. Silverman, "The Organic Chemistry of Drug Design and Drug Action, Academic Press, San Diego, CA, U.S.A., pgs. 352-401, (1992)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Oraw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH /LLS/

Examiner Signature /Laura L. Stockton/	Date Considered	01/25/2010